The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling

Oncotarget

Volumn 5, Issue 6, 2014, Pages 1666-1682

  Correa, Ricardo G ^a   Krajewska, Maryla ^a   Ware, Carl F ^a   Gerlic, Motti ^a,b   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

AR; NLR; PDEF; Prostate; SRY

Indexed keywords

ANDROGEN RECEPTOR; MEMBRANE PROTEIN; PACLITAXEL; PROTEIN NWD1; TESTIS DETERMINING FACTOR; UNCLASSIFIED DRUG; ANDROGEN; AR PROTEIN, HUMAN; MESSENGER RNA; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SPDEF PROTEIN, HUMAN; SRY PROTEIN, HUMAN; TRANSCRIPTION FACTOR ETS;

ARTICLE; CANCER GROWTH; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME REPRESSION; GENE CONTROL; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; SIGNAL TRANSDUCTION; UPREGULATION; ADENOCARCINOMA; ANIMAL; APOPTOSIS; CASTRATION RESISTANT PROSTATE CANCER; CELL CULTURE; CELL PROLIFERATION; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; IMMUNOPRECIPITATION; LIQUID CHROMATOGRAPHY; METABOLISM; MOUSE; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ANDROGENS; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELLS, CULTURED; CHROMATOGRAPHY, LIQUID; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MALE; MICE; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; PROTEOMICS; PROTO-ONCOGENE PROTEINS C-ETS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEX-DETERMINING REGION Y PROTEIN; SIGNAL TRANSDUCTION; TANDEM MASS SPECTROMETRY;

EID: 84904267838     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1850     Document Type: Article

References (69)

1. da Silva HB, Amaral EP, Nolasco EL, de Victo NC, Atique R, Jank CC, Anschau V, Zerbini LF and Correa RG. Dissecting Major Signaling Pathways throughout the Development of Prostate Cancer. Prostate cancer. 2013; 2013:920612.
2. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG and Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004; 10(1):33-39.
3. Li TH, Zhao H, Peng Y, Beliakoff J, Brooks JD and Sun Z. A promoting role of androgen receptor in androgen-sensitive and -insensitive prostate cancer cells. Nucleic acids research. 2007; 35(8):2767-2776.
4. Kanneganti TD, Lamkanfi M and Nunez G. Intracellular NOD-like receptors in host defense and disease. Immunity. 2007; 27(4):549-559.
5. Ting JP, Lovering RC, Alnemri ES, Bertin J, Boss JM, Davis BK, Flavell RA, Girardin SE, Godzik A, Harton JA, Hoffman HM, Hugot JP, Inohara N, Mackenzie A, Maltais LJ, Nunez G, et al. The NLR gene family: a standard nomenclature. Immunity. 2008; 28(3):285-287.
6. Creagh EM and O'Neill LA. TLRs, NLRs and RLRs: a trinity of pathogen sensors that co-operate in innate immunity. Trends Immunol. 2006; 27(8):352-357.
7. Murray PJ. NOD proteins: an intracellular pathogen-recognition system or signal transduction modifiers? Curr Opin Immunol. 2005; 17(4):352-358.
8. Martinon F and Tschopp J. Inflammatory caspases and inflammasomes: master switches of inflammation. Cell Death Differ. 2007; 14(1):10-22.
9. Petrilli V, Dostert C, Muruve DA and Tschopp J. The inflammasome: a danger sensing complex triggering innate immunity. Curr Opin Immunol. 2007; 19(6):615-622.
10. Tattoli I, Travassos LH, Carneiro LA, Magalhaes JG and Girardin SE. The Nodosome: Nod1 and Nod2 control bacterial infections and inflammation. Semin Immunopathol. 2007; 29(3):289-301.
11. Carneiro L, Magalhaes J, Tattoli I, Philpott D and Travassos L. Nod-like proteins in inflammation and disease. J Pathol. 2008; 214(2):136-148.
12. Davis BK, Wen H and Ting JP. The inflammasome NLRs in immunity, inflammation, and associated diseases. Annu Rev Immunol. 2011; 29:707-735.
13. da Silva Correia J, Miranda Y, Austin-Brown N, Hsu J, Mathison J, Xiang R, Zhou H, Li Q, Han J and Ulevitch RJ. Nod1-dependent control of tumor growth. Proc Natl Acad Sci U S A. 2006; 103(6):1840-1845.
14. Allen IC, Wilson JE, Schneider M, Lich JD, Roberts RA, Arthur JC, Woodford RM, Davis BK, Uronis JM, Herfarth HH, Jobin C, Rogers AB and Ting JP. NLRP12 suppresses colon inflammation and tumorigenesis through the negative regulation of noncanonical NF-kappaB signaling. Immunity. 2012; 36(5):742-754.
15. Kutikhin AG. Role of NOD1/CARD4 and NOD2/CARD15 gene polymorphisms in cancer etiology. Hum Immunol. 2011; 72(10):955-968.
16. Kang MJ, Heo SK, Song EJ, Kim DJ, Han SY, Han JH, Kim BY and Park JH. Activation of Nod1 and Nod2 induces innate immune responses of prostate epithelial cells. Prostate. 2012.
17. Kufer TA, Fritz JH and Philpott DJ. NACHT-LRR proteins (NLRs) in bacterial infection and immunity. Trends Microbiol. 2005; 13(8):381-388.
18. Correa RG, Milutinovic S and Reed JC. Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases. Bioscience reports. 2012; 32(6):597- 608.
19. Inohara, Chamaillard, McDonald C and Nunez G. NOD-LRR proteins: role in host-microbial interactions and inflammatory disease. Annu Rev Biochem. 2005; 74:355- 383.
20. Carneiro LA, Travassos LH and Girardin SE. Nod-like receptors in innate immunity and inflammatory diseases. Ann Med. 2007; 39(8):581-593.
21. Stein C, Caccamo M, Laird G and Leptin M. Conservation and divergence of gene families encoding components of innate immune response systems in zebrafish. Genome Biol. 2007; 8(11):R251.
22. Zou H, Henzel WJ, Liu X, Lutschg A and Wang X. Apaf- 1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 1997; 90(3):405-413.
23. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV, Ignatieva EV, Ananko EA, Podkolodnaya OA, Kolpakov FA, Podkolodny NL and Kolchanov NA. Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic acids research. 1998; 26(1):362-367.
24. Matzuk MM and Lamb DJ. The biology of infertility: research advances and clinical challenges. Nat Med. 2008; 14(11):1197-1213.
25. Guth SI and Wegner M. Having it both ways: Sox protein function between conservation and innovation. Cellular and molecular life sciences: CMLS. 2008; 65(19):3000-3018.
26. Yuan X, Lu ML, Li T and Balk SP. SRY interacts with and negatively regulates androgen receptor transcriptional activity. J Biol Chem. 2001; 276(49):46647-46654.
27. Brothman AR, Wilkins PC, Sales EW and Somers KD. Metastatic properties of the human prostatic cell line, PPC- 1, in athymic nude mice. The Journal of urology. 1991; 145(5):1088-1091.
28. Ting JP, Willingham SB and Bergstralh DT. NLRs at the intersection of cell death and immunity. Nat Rev Immunol. 2008; 8(5):372-379.
29. Oettgen P, Finger E, Sun Z, Akbarali Y, Thamrongsak U, Boltax J, Grall F, Dube A, Weiss A, Brown L, Quinn G, Kas K, Endress G, Kunsch C and Libermann TA. PDEF, a novel prostate epithelium-specific ets transcription factor, interacts with the androgen receptor and activates prostate-specific antigen gene expression. J Biol Chem. 2000; 275(2):1216-1225.
30. Sood AK, Kim H and Geradts J. PDEF in prostate cancer. Prostate. 2012; 72(6):592-596.
31. Sood AK, Saxena R, Groth J, Desouki MM, Cheewakriangkrai C, Rodabaugh KJ, Kasyapa CS and Geradts J. Expression characteristics of prostate-derived Ets factor support a role in breast and prostate cancer progression. Human pathology. 2007; 38(11):1628-1638.
32. Ngan S, Stronach EA, Photiou A, Waxman J, Ali S and Buluwela L. Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene. 2009; 28(19):2051-2063.
33. Dehm SM and Tindall DJ. Alternatively spliced androgen receptor variants. Endocrine-related cancer. 2011; 18(5):R183-196.
34. Balk SP, Ko YJ and Bubley GJ. Biology of prostate-specific antigen. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003; 21(2):383- 391.
35. Jasavala R, Martinez H, Thumar J, Andaya A, Gingras AC, Eng JK, Aebersold R, Han DK and Wright ME. Identification of putative androgen receptor interaction protein modules: cytoskeleton and endosomes modulate androgen receptor signaling in prostate cancer cells. Molecular & cellular proteomics: MCP. 2007; 6(2):252- 271.
36. Burnstein KL. Regulation of androgen receptor levels: implications for prostate cancer progression and therapy. Journal of cellular biochemistry. 2005; 95(4):657-669.
37. Reddy GP, Barrack ER, Dou QP, Menon M, Pelley R, Sarkar FH and Sheng S. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer. Journal of cellular biochemistry. 2006; 98(6):1408-1423.
38. Rajendran KV, Zhang J, Liu S, Kucuktas H, Wang X, Liu H, Sha Z, Terhune J, Peatman E and Liu Z. Pathogen recognition receptors in channel catfish: I. Identification, phylogeny and expression of NOD-like receptors. Developmental and comparative immunology. 2012; 37(1):77-86.
39. Lange C, Hemmrich G, Klostermeier UC, Lopez-Quintero JA, Miller DJ, Rahn T, Weiss Y, Bosch TC and Rosenstiel P. Defining the origins of the NOD-like receptor system at the base of animal evolution. Molecular biology and evolution. 2011; 28(5):1687-1702.
40. Laing KJ, Purcell MK, Winton JR and Hansen JD. A genomic view of the NOD-like receptor family in teleost fish: identification of a novel NLR subfamily in zebrafish. BMC evolutionary biology. 2008; 8:42.
41. Hu Y, Ding L, Spencer DM and Nunez G. WD-40 repeat region regulates Apaf-1 self-association and procaspase-9 activation. J Biol Chem. 1998; 273(50):33489-33494.
42. Bolton KL, Tyrer J, Song H, Ramus SJ, Notaridou M, Jones C, Sher T, Gentry-Maharaj A, Wozniak E, Tsai YY, Weidhaas J, Paik D, Van Den Berg DJ, Stram DO, Pearce CL, Wu AH, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nature genetics. 2010; 42(10):880-884.
43. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, Orr N, Rhie SK, Riboli E, Feigelson HS, Le Marchand L, Buring JE, Eccles D, Miron P, Fasching PA, Brauch H, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nature genetics. 2013; 45(4):392-398, 398e391-392.
44. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL, Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, Wang Q, Dicks E, Lee A, Turnbull C, Rahman N, Breast, et al. Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature genetics. 2013; 45(4):353-361, 361e351-352.
45. Pharoah PD, Tsai YY, Ramus SJ, Phelan CM, Goode EL, Lawrenson K, Buckley M, Fridley BL, Tyrer JP, Shen H, Weber R, Karevan R, Larson MC, Song H, Tessier DC, Bacot F, et al. GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature genetics. 2013; 45(4):362-370, 370e361-362.
46. Prasad A, Merico D, Thiruvahindrapuram B, Wei J, Lionel AC, Sato D, Rickaby J, Lu C, Szatmari P, Roberts W, Fernandez BA, Marshall CR, Hatchwell E, Eis PS and Scherer SW. A discovery resource of rare copy number variations in individuals with autism spectrum disorder. G3. 2012; 2(12):1665-1685.
47. Gallant NM, Baldwin E, Salamon N, Dipple KM and Quintero-Rivera F. Pontocerebellar hypoplasia in association with de novo 19p13.11p13.12 microdeletion. American journal of medical genetics Part A. 2011; 155A(11):2871-2878.
48. Lech M, Avila-Ferrufino A, Skuginna V, Susanti HE and Anders HJ. Quantitative expression of RIG-like helicase, NOD-like receptor and inflammasome-related mRNAs in humans and mice. Int Immunol. 2010; 22(9):717-728.
49. Slim R and Wallace EP. NLRP7 and the Genetics of Hydatidiform Moles: Recent Advances and New Challenges. Frontiers in immunology. 2013; 4:242.
50. Kanai Y, Hiramatsu R, Matoba S and Kidokoro T. From SRY to SOX9: mammalian testis differentiation. Journal of biochemistry. 2005; 138(1):13-19.
51. Tricoli JV, Yao JL, D'Souza SA and Bracken RB. Detection of sex-region Y (SRY) transcripts in human prostate adenocarcinoma and benign prostatic hypertrophy. Genes, chromosomes & cancer. 1993; 8(1):28-33.
52. Perinchery G, Sasaki M, Angan A, Kumar V, Carroll P and Dahiya R. Deletion of Y-chromosome specific genes in human prostate cancer. The Journal of urology. 2000; 163(4):1339-1342.
53. Jordan JJ, Hanlon AL, Al-Saleem TI, Greenberg RE and Tricoli JV. Loss of the short arm of the Y chromosome in human prostate carcinoma. Cancer genetics and cytogenetics. 2001; 124(2):122-126.
54. Thomsen MK, Ambroisine L, Wynn S, Cheah KS, Foster CS, Fisher G, Berney DM, Moller H, Reuter VE, Scardino P, Cuzick J, Ragavan N, Singh PB, Martin FL, Butler CM, Cooper CS, et al. SOX9 elevation in the prostate promotes proliferation and cooperates with PTEN loss to drive tumor formation. Cancer Res. 2010; 70(3):979-987.
55. Krajewska M, Turner BC, Shabaik A, Krajewski S and Reed JC. Expression of BAG-1 protein correlates with aggressive behavior of prostate cancers. Prostate. 2006; 66(8):801-810.
56. Krajewska M, Kitada S, Winter JN, Variakojis D, Lichtenstein A, Zhai D, Cuddy M, Huang X, Luciano F, Baker CH, Kim H, Shin E, Kennedy S, Olson AH, Badzio A, Jassem J, et al. Bcl-B expression in human epithelial and nonepithelial malignancies. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(10):3011-3021.
57. Ghadersohi A, Sharma S, Zhang S, Azrak RG, Wilding GE, Manjili MH and Li F. Prostate-derived Ets transcription factor (PDEF) is a potential prognostic marker in patients with prostate cancer. Prostate. 2011; 71(11):1178-1188.
58. Turner DP, Findlay VJ, Moussa O, Semenchenko VI, Watson PM, LaRue AC, Desouki MM, Fraig M and Watson DK. Mechanisms and functional consequences of PDEF protein expression loss during prostate cancer progression. Prostate. 2011; 71(16):1723-1735.
59. Chen H, Nandi AK, Li X and Bieberich CJ. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res. 2002; 62(2):338- 340.
60. Prescott J and Coetzee GA. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer letters. 2006; 231(1):12-19.
61. Hudson AM and Cooley L. Phylogenetic, structural and functional relationships between WD- and Kelch-repeat proteins. Sub-cellular biochemistry. 2008; 48:6-19.
62. Faustin B, Lartigue L, Bruey JM, Luciano F, Sergienko E, Bailly-Maitre B, Volkmann N, Hanein D, Rouiller I and Reed JC. Reconstituted NALP1 inflammasome reveals two-step mechanism of caspase-1 activation. Mol Cell. 2007; 25(5):713-724.
63. Faustin B, Chen Y, Zhai D, Le Negrate G, Lartigue L, Satterthwait A and Reed JC. Mechanism of Bcl-2 and Bcl- X(L) inhibition of NLRP1 inflammasome: loop domain-dependent suppression of ATP binding and oligomerization. Proc Natl Acad Sci U S A. 2009; 106(10):3935-3940.
64. Tiscornia G, Singer O, Ikawa M and Verma IM. A general method for gene knockdown in mice by using lentiviral vectors expressing small interfering RNA. Proc Natl Acad Sci U S A. 2003; 100(4):1844-1848.
65. Tiscornia G, Singer O and Verma IM. Production and purification of lentiviral vectors. Nature protocols. 2006; 1(1):241-245.
66. Krajewska M, Kim H, Shin E, Kennedy S, Duffy MJ, Wong YF, Marr D, Mikolajczyk J, Shabaik A, Meinhold-Heerlein I, Huang X, Banares S, Hedayat H, Reed JC and Krajewski S. Tumor-associated alterations in caspase-14 expression in epithelial malignancies. Clinical cancer research: an official journal of the American Association for Cancer Research. 2005; 11(15):5462-5471.
67. Pio R, Jia Z, Baron VT, Mercola D and Cancer UNSCotSPftEoCS-P. Early growth response 3(Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancer. PLoS One. 2013; 8(1):e54096.
68. Krajewska M, Smith LH, Rong J, Huang X, Hyer ML, Zeps N, Iacopetta B, Linke SP, Olson AH, Reed JC and Krajewski S. Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections. The journal of histochemistry and cytochemistry: official journal of the Histochemistry Society. 2009; 57(7):649-663.
69. Brill LM, Motamedchaboki K, Wu S and Wolf DA. Comprehensive proteomic analysis of Schizosaccharomyces pombe by two-dimensional HPLC-tandem mass spectrometry. Methods. 2009; 48(3):311-319.